MAASH, a fermentation company developing mycoprotein for the food industry, has secured €12.15 million in a Series A funding round, combining €5.85 million in equity from investors like Ambra Capital and Bpifrance, with €4.3 million in public financing and a €2 million loan. This funding marks MAASH's transition from project development to industrial execution at its acquired former Metabolic Explorer site. The capital will accelerate commercial rollout and build a cost-competitive platform, with Samah Garringer appointed as CEO to lead this expansion.